Cantor Fitzgerald maintains Overweight on ORIC stock
Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to InvestingPro data ...
Cantor says Oric accidental release looks ‘very positive’ for mevrometostat
Cantor Fitzgerald notes that the firm discovered “what appears” to be an “accidental release” of a snippet on the ASCO-GU daily news website ...
ETF Daily News21d
Cantor Fitzgerald Predicts ORIC FY2025 Earnings
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for ORIC Pharmaceuticals in a report ...
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC) and Biogen (BIIB)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oric Pharmaceuticals (ORIC – Research Report) ...
Guggenheim Reiterates “Buy” Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Guggenheim in a research report issued to clients and investors on Monday,Benzinga reports.
Investing9d
Cantor Fitzgerald maintains Overweight on ORIC shares, sees upside
On Tuesday, Cantor Fitzgerald reiterated its confidence in ORIC Pharmaceuticals (NASDAQ:ORIC), maintaining an Overweight stock rating. Trading at $11.49, ORIC has seen analyst targets ranging from $13 ...